Short‐term efficacy, safety, and cost‐effectiveness of transarterial chemoembolization with drug‐eluting beads versus synchronous radiochemotherapy for cervical cancer

Abstract

Objective To investigate the short‐term efficacy and safety of transarterial chemoembolization with drug‐eluting beads (DEB‐TACE) versus synchronous radiochemotherapy among women with cervical cancer. Methods A retrospective cohort study of women treated by synchronous radiochemotherapy (n=20) and DEB‐TACE (n=20) at a single center in China between November 2015 and September 2017. Inclusion criteria were pathologic diagnosis of cervical cancer, age at least 18 years, and complete clinicopathologic information. Hospital stay, direct medical cost, resection frequency, adverse events, treatment responses, progression‐free survival (PFS) and overall survival (OS) were compared between treatments. Results There was no difference in treatment responses, PFS, or OS between the two groups. Hospital stay was shorter, direct medical costs were lower, and resection rate was higher in the DEB‐TACE group than in the radiochemotherapy group (all P<0.05). In univariate and multivariate logistic regression analysis, no factor was associated with complete response. No predictive factor for PFS or OS was identified by Cox proportional regression analysis. Fewer adverse advents were recorded in the DEB‐TACE group than in the synchronous radiochemotherapy group. Conclusion Among women with cervical cancer, DEB‐TACE achieved equal short‐term efficacy, better tolerance, less hospital stay and medical costs, and higher resection rates as compared with synchronous radiochemotherapy.

Targeting HMGB3/hTERT axis for radioresistance in cervical cancer

“…Chemotherapy is also very important for cervical cancertreatment [26,27]. We next determined the effect of HMGB3 on sensitivity of cervical cancer cells to three common chemotherapeutic drugs.…”

Drug-eluting beads-transcatheter arterial chemoembolization with or without iodine-125 treatment is effective and tolerable in treating advanced non-small cell lung cancer patients: a pilot study

“…Secondly, the comparison of efficacy and safety between DEB-TACE and other chemoembolization methods (such as conventional transcatheter arterial chemoembolization or transpulmonary chemoembolization) was not explored. Thirdly, the use of DEB-TACE from bronchial artery was not established, however, there have been studies illustrating that DEB-TACE was tolerable and effective in tumors supplied by bronchial arteries, including NSCLC ( 22 , 24 , 25 ). Fourthly, the grading of AEs was not performed in our study, however, the primary aim of ours was to assess the incidence of AEs; besides, the number of AEs was small and most of which were tolerable.…”

Oncopharmacology in Interventional Radiology

“…16 17 18 Additionally, TACE has also been described in primary lung, gynecologic, prostate, and renal cell malignancies, bone/soft tissue sarcoma, and retinoblastomas. 19 20 21 22 23 24…”